Enanta Pharma (NASDAQ:ENTA) is preparing to release its quarterly earnings on Monday, 2026-02-09. Here's a brief overview of what investors should keep in mind before the announcement.

Analysts expect Enanta Pharma to report an earnings per share (EPS) of $-0.74.

Investors in Enanta Pharma are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.

It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.

Performance in Previous Earnings

During the last quarter, the company reported an EPS beat by $0.19, leading to a 3.59% drop in the share price on the subsequent day.

Here's a look at Enanta Pharma's past performance and the resulting price change:

Quarter	Q4 2025	Q3 2025	Q2 2025	Q1 2025
EPS Estimate	-1.06	-1.03	-1.46	-1.35
EPS Actual	-0.87	-0.85	-1.06	-1.05
Price Change %	-4.00	6.00	-6.00	14.00

Market Performance of Enanta Pharma's Stock

Shares of Enanta Pharma were trading at $12.97 as of February 05. Over the last 52-week period, shares are up 174.08%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.

Analyst Opinions on Enanta Pharma

For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Enanta Pharma.

Analysts have given Enanta Pharma a total of 2 ratings, with the consensus rating being Buy. The average one-year price target is $18.5, indicating a potential 42.64% upside.

Analyzing Ratings Among Peers

In this analysis, we delve into the analyst ratings and average 1-year price targets of and Lineage Cell Therapeutics, three key industry players, offering insights into their relative performance expectations and market positioning.

Insights: Peer Analysis

The peer analysis summary outlines pivotal metrics for and Lineage Cell Therapeutics, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

Company	Consensus	Revenue Growth	Gross Profit	Return on Equity
Lineage Cell Therapeutics	Buy	-2.59%	$3.68M	-84.58%

Key Takeaway:

Enanta Pharma ranks at the top for Consensus rating among its peers. It is in the middle for Revenue Growth. Enanta Pharma is at the bottom for Gross Profit and Return on Equity compared to its peers.

Unveiling the Story Behind Enanta Pharma

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Enanta Pharma's Financial Performance

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Enanta Pharma's remarkable performance in 3 months is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of 3.55%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Enanta Pharma's net margin is impressive, surpassing industry averages. With a net margin of -123.64%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -25.97%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -6.43%, the company showcases effective utilization of assets.

Debt Management: With a high debt-to-equity ratio of 0.89, Enanta Pharma faces challenges in effectively managing its debt levels, indicating potential financial strain.

To track all earnings releases for Enanta Pharma visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.